MXPA03011908A - Derivados de tetrahidroquinolina. - Google Patents

Derivados de tetrahidroquinolina.

Info

Publication number
MXPA03011908A
MXPA03011908A MXPA03011908A MXPA03011908A MXPA03011908A MX PA03011908 A MXPA03011908 A MX PA03011908A MX PA03011908 A MXPA03011908 A MX PA03011908A MX PA03011908 A MXPA03011908 A MX PA03011908A MX PA03011908 A MXPA03011908 A MX PA03011908A
Authority
MX
Mexico
Prior art keywords
alkyl
nhc
heteroaryl
cycloalkyl
aryl
Prior art date
Application number
MXPA03011908A
Other languages
English (en)
Inventor
Corine Rene Van Straten Nicole
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of MXPA03011908A publication Critical patent/MXPA03011908A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

La presente invencion se refiere a derivados de tetrahidroquinolina que tienen la formula general (I) o una sal farmaceuticamente aceptable de la misma, en donde R1 es formilo, (1-6C)alquilcarbonilo o (1-6C)alquilsulfonilo; R2 y R3 son H o (1-4C)alquilo; R4 es fenilo, R5 es (1-4C)alquilo; Y-X es C(O)-O, (SO)2-O, NHC(O)-O, NHC(S)-O, OC(O)-O, enlace-O, C(O)-NH, S(O)2-NH, NHC(O)-NH, NHC(S)-NH, OC(O)-NH, enlace-NH, NH-C(O), O-C(O), NH-S(O)2, o O-S(O)2 o X-Y es un enlace; R6 es H, trifluorometilo, (1-6)alquilo, 1- o 2-adamantil(1-4C)alquilo, (2-6C)alqueniloI, (3-9C) heteroariIo, (3-6C) cicloaIquiIo, (2-6C)heterocicloaIquilo, (1-4C)alquiltio (1-4C)alquilo, (6-10C)aril(1-4C)alquilo, (3-9C)heteroaril(1-4C)alquilo, (3-6C)cicloalquil(1-4C)alquilo, (2-6C)heterocicloatlquil(-1-4C)alquilo, R8, R9-aminocarbonil(1-4C)alquilo, R8, R9-amino(1-4C)alquilo, R8-oxicarbonil(1-4C) aiquilo, R8-oxi(1-4C)alquilo, R8-carbonil(1-4C)alquilo o (6-10C)ariio, R7 es H, (1-4C)alquilo, (1-4C)alcoxil halogeno, trifluorometilo, ciano, nitro, hidroxilo; y R8 y/o R9 es H, (1-4C)alquilo, (2-4C)alquenilo, (2-4C)alquinilo, (6-10C)arilo, (3-9C) heteroarilo, (6-10C)ariI (1-4C)aIquiIo, (3-9C) heteroariI (1-4C)aIquilo, (3-6C)cicloalquil(1-4C)alquilo, (2-6C)heterocicloaIquil(1-4C)atquilol (1-4C)(di)alquilamino(1-4C)alquilo, (1-4C)alcoxi(1-4C)alquilo, (1-4C)alquilito(1-4C)alquilo, (1-4C)alquilcarbonilamino(1-4C)alquilo, (1-4C)alcoxicarbonil(1-4C)alquilo, (1-4C)alcoxicarbonliamino(1-4C)alquilo, (3-6C)cicloaiquiio, (2- 6C)heterocicloalquilo, o R8 y R9 pueden unirse en una cadena de (2-6C)heterocicloalquilo. La presente invencion tambien se refiere a composiciones farmaceuticas que comprende dichos derivados y el uso de estos derivados para controlar la fertilidad.
MXPA03011908A 2001-07-02 2002-06-25 Derivados de tetrahidroquinolina. MXPA03011908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202531 2001-07-02
PCT/EP2002/007053 WO2003004028A1 (en) 2001-07-02 2002-06-25 Tetrahydroquinoline derivatives

Publications (1)

Publication Number Publication Date
MXPA03011908A true MXPA03011908A (es) 2004-06-03

Family

ID=8180574

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011908A MXPA03011908A (es) 2001-07-02 2002-06-25 Derivados de tetrahidroquinolina.

Country Status (32)

Country Link
US (2) US8058441B2 (es)
EP (1) EP1406628B1 (es)
JP (1) JP4523273B2 (es)
KR (1) KR100908468B1 (es)
CN (1) CN1261099C (es)
AR (1) AR034669A1 (es)
AT (1) ATE319451T1 (es)
AU (1) AU2002317848B2 (es)
BR (1) BR0210645A (es)
CA (1) CA2452606C (es)
CY (1) CY1106087T1 (es)
CZ (1) CZ20042A3 (es)
DE (1) DE60209734T2 (es)
DK (1) DK1406628T3 (es)
EC (1) ECSP034932A (es)
ES (1) ES2260458T3 (es)
HK (1) HK1061810A1 (es)
HR (1) HRP20031080A2 (es)
HU (1) HUP0400390A2 (es)
IL (1) IL159288A0 (es)
IS (1) IS2418B (es)
MX (1) MXPA03011908A (es)
NO (1) NO325516B1 (es)
NZ (1) NZ530198A (es)
PE (1) PE20030273A1 (es)
PL (1) PL367638A1 (es)
PT (1) PT1406628E (es)
RU (1) RU2347570C2 (es)
SA (1) SA02230260B1 (es)
SK (1) SK286759B6 (es)
WO (1) WO2003004028A1 (es)
ZA (1) ZA200309921B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406628B1 (en) 2001-07-02 2006-03-08 Akzo Nobel N.V. Tetrahydroquinoline derivatives
DE60325025D1 (de) * 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
FR2836620B1 (fr) * 2002-02-28 2004-04-16 Snecma Services Instrument de projection thermique
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105798A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
JP4869336B2 (ja) 2005-05-04 2012-02-08 ナームローゼ・フエンノートチヤツプ・オルガノン ジヒドロピリジン誘導体
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
UA92007C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
UA92009C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
MX2007014085A (es) 2005-05-12 2008-02-07 Wyeth Corp Pirrolobenzodiazepinas y derivados de carboxamida heterociclica como antagonistas de receptor de hormona estimulante del foliculo.
MX2007015643A (es) 2005-06-09 2008-02-15 Wyeth Corp Pirrolobenzodiazepinpiridincarboxamidas y derivados como antagonistas de receptor de hormona estimulante del foliculo.
US20070060573A1 (en) * 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
US20080221195A1 (en) * 2006-12-13 2008-09-11 Lars Wortmann 1,2-diarylacetylene derivatives of acyltryptophanols
EP1932831A1 (en) * 2006-12-13 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylacetylene Derivatives of Acyltryptophanols
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
AU2008228067B2 (en) * 2007-03-22 2011-12-08 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
WO2012048181A1 (en) * 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
US8546427B2 (en) * 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
EP3174932B1 (en) 2014-07-30 2021-06-09 Henkel IP & Holding GmbH Cure accelerators for anaerobic curable compositions
US20210179607A1 (en) * 2017-11-01 2021-06-17 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2686182A (en) 1950-12-07 1954-08-10 Basf Ag O-hydroxy-dihydro-quinoline carboxylic acids
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE69531998T2 (de) * 1994-12-22 2004-07-22 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-modulator verbindungen und methoden
IL141063A (en) * 1998-08-07 2005-06-19 Applied Research Systems Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
JP2000143636A (ja) * 1998-09-02 2000-05-26 Sumitomo Pharmaceut Co Ltd アミノ誘導体
US6200963B1 (en) * 1999-03-31 2001-03-13 American Home Products Corporation Aryl sulfonic acids as FSH antagonists
EP1406628B1 (en) 2001-07-02 2006-03-08 Akzo Nobel N.V. Tetrahydroquinoline derivatives
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
SK16342003A3 (sk) 2004-07-07
RU2004102693A (ru) 2005-06-27
CA2452606A1 (en) 2003-01-16
BR0210645A (pt) 2004-10-05
SK286759B6 (sk) 2009-05-07
KR20040030714A (ko) 2004-04-09
US8058441B2 (en) 2011-11-15
ZA200309921B (en) 2005-03-22
SA02230260B1 (ar) 2007-03-25
HRP20031080A2 (en) 2004-04-30
JP4523273B2 (ja) 2010-08-11
KR100908468B1 (ko) 2009-07-21
EP1406628B1 (en) 2006-03-08
AR034669A1 (es) 2004-03-03
PL367638A1 (en) 2005-03-07
HK1061810A1 (en) 2004-10-08
WO2003004028A1 (en) 2003-01-16
DE60209734D1 (de) 2006-05-04
PE20030273A1 (es) 2003-03-21
EP1406628A1 (en) 2004-04-14
ES2260458T3 (es) 2006-11-01
NO325516B1 (no) 2008-06-02
CY1106087T1 (el) 2011-06-08
ECSP034932A (es) 2004-02-26
DK1406628T3 (da) 2006-07-03
DE60209734T2 (de) 2006-08-31
IS2418B (is) 2008-10-15
US20120202996A1 (en) 2012-08-09
CN1261099C (zh) 2006-06-28
NZ530198A (en) 2005-11-25
US20040236109A1 (en) 2004-11-25
AU2002317848B2 (en) 2006-08-31
PT1406628E (pt) 2006-06-30
ATE319451T1 (de) 2006-03-15
US8258293B2 (en) 2012-09-04
HUP0400390A2 (hu) 2004-09-28
JP2004535456A (ja) 2004-11-25
IS7071A (is) 2003-12-11
NO20035763L (no) 2003-12-29
CZ20042A3 (en) 2004-04-14
RU2347570C2 (ru) 2009-02-27
IL159288A0 (en) 2004-06-01
CN1529601A (zh) 2004-09-15
CA2452606C (en) 2011-09-13

Similar Documents

Publication Publication Date Title
MXPA03011908A (es) Derivados de tetrahidroquinolina.
MX9700883A (es) Derivados sustituidos de la quinazolina.
EP1566379A4 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
WO2002081448A1 (fr) Derive benzamidine
WO2006034341A3 (en) Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
EP1243582A4 (en) CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
HK1065540A1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
GB2424882A (en) Selective kinase inhibitors
DE602004024375D1 (de) Carboxamidderivate
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
ATE302775T1 (de) Carbolinderivate
WO2001009103A3 (en) Imidazole antiproliferative agents
HUP0402336A2 (hu) Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
MXPA03011510A (es) Derivados de5-halo-triptamina usados como ligandos de receptores de serotonina 5-ht-6 y/o 5-ht-7.
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
ATE346067T1 (de) Carbolinderivate
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights